Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 2.4% – Time to Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) traded down 2.4% during mid-day trading on Monday . The company traded as low as $2.42 and last traded at $2.47. Approximately 20,474 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 29,731 shares. The stock had previously closed at $2.53.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Kiora Pharmaceuticals Price Performance

The stock has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $2.26. The firm has a market capitalization of $10.94 million, a P/E ratio of -0.91 and a beta of -0.40.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.58).

Institutional Investors Weigh In On Kiora Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new stake in Kiora Pharmaceuticals in the third quarter worth $33,000. Renaissance Technologies LLC raised its holdings in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after purchasing an additional 8,800 shares during the period. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals during the third quarter valued at about $125,000. Alyeska Investment Group L.P. bought a new position in shares of Kiora Pharmaceuticals during the 4th quarter worth about $152,000. Finally, DRW Securities LLC boosted its position in shares of Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares in the last quarter. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.